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The ambr® 250 bioreactor system (Sartorius Stedim) has become a useful tool for CHO cell culture process 
development, increasing throughput and decreasing development timelines. The ambr® 250 provides the ability 
to independently run up to 24 single-use fed-batch bioreactors through the use of an automated liquid handling 
platform. Growing interest in intensified perfusion processes for continuous biomanufacturing has created a 
need for an equivalent high throughput small scale system for perfusion.  Thus far, only discrete models and 
semi-continuous approaches have been available to mimic perfusion processes at small scale.  With the 
development of the ambr® 250 perfusion system, truly continuous medium exchange and cell retention at the 
200mL scale has been achieved. Primary criteria for evaluating the applicability of the ambr® 250 perfusion 
system to modeling larger scale intensified perfusion processes include viable cell density and volumetric 
productivity.  We have demonstrated the development system can support growth of CHO cell cultures in 
excess of 90 million cells per milliliter with IgG volumetric productivity greater than 3 g/L/day. These results are 
comparable to data obtained at the 10L scale.  Sustainability of culture, impact on product quality, and potential 
use for applications ranging from clone selection to scale-down modeling will be discussed. 
 
